Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYM1J4
|
|||
| Drug Name |
ASP7517
|
|||
| Drug Type |
Cell therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1/2 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Company |
Astellas Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04079296) A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.